Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 4/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.44 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20144832 | 1.00 | HCRTR2 (0.45) | HCRTR2CCR6HCRTR1MAP3K12KMT2A | |
| SCHEMBL20145111 | 0.90 | CDK12 (0.46) | HCRTR2HCRTR1KMT2AGAA | |
| SCHEMBL16155578 | 0.82 | HCRTR2 (0.67) | HCRTR2HCRTR1 | |
| SCHEMBL18697634 | 0.80 | HCRTR2 (0.69) | HCRTR2HCRTR1KMT2A | |
| SCHEMBL20144748 | 0.80 | HCRTR2 (0.69) | HCRTR2HCRTR1KMT2A | |
| SCHEMBL18697655 | 0.78 | HCRTR1 (0.71) | HCRTR2HCRTR1 | |
| SCHEMBL20144746 | 0.78 | HCRTR1 (0.71) | HCRTR2HCRTR1 | |
| SCHEMBL20144784 | 0.77 | HCRTR2 (0.69) | HCRTR2HCRTR1MAP3K12 | |
| SCHEMBL18697642 | 0.77 | HCRTR2 (0.69) | HCRTR2HCRTR1MAP3K12 | |
| SCHEMBL18697657 | 0.77 | HCRTR1 (0.70) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970207-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-16 | — | — | EP | disclosed |